NIASPAN TABLET (EXTENDED-RELEASE)
Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Súhrn charakteristických
(SPC)
23-10-2015
Niektoré dokumenty týkajúce sa tohto produktu nie sú momentálne k dispozícii, môžete poslať požiadavku na náš zákaznícky servis a my vás upozorníme hneď, ako ich dokážeme získať.
Poslať žiadosť.
Poslať žiadosť.
Aktívna zložka:
NICOTINIC ACID
Dostupné z:
SUNOVION PHARMACEUTICALS CANADA INC
ATC kód:
C10AD02
INN (Medzinárodný Name):
NICOTINIC ACID
Dávkovanie:
1000MG
Forma lieku:
TABLET (EXTENDED-RELEASE)
Zloženie:
NICOTINIC ACID 1000MG
Spôsob podávania:
ORAL
Počet v balení:
30
Typ predpisu:
Prescription
Terapeutické oblasti:
MISCELLANEOUS ANTILIPEMIC AGENTS
Prehľad produktov:
Active ingredient group (AIG) number: 0108396010; AHFS:
Stav Autorizácia:
CANCELLED POST MARKET
Dátum Autorizácia:
2017-06-30
Súhrn charakteristických
PRODUCT MONOGRAPH
PR
NIASPAN
®
Extended-Release Niacin
500 mg and 1000 mg Extended-Release Tablets
Lipid Metabolism Regulator
Manufacturer:
DATE OF REVISION:
Sunovion Pharmaceuticals Canada Inc.
October 23, 2015
6790 Century Ave. Suite 100
Mississauga, Ontario
Canada
Submission #: 185768
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
7
DRUG INTERACTIONS
..........................................................................................................
11
DOSAGE AND ADMINISTRATION
......................................................................................
12
OVERDOSAGE
........................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
14
STORAGE AND STABILITY
.................................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 16
PART II: SCIENTIFIC INFORMATION
..............................................................................
17
PHARMACEUTICAL INFORMATION
.................................................................................
17
CLINICAL
TRIALS...............................................................................................
Prečítajte si celý dokument
